Free Trial
NASDAQ:BMEA

Biomea Fusion Q1 2025 Earnings Results & Report

Biomea Fusion logo
$0.60 +0.05 (+9.69%)
As of 10:58 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Biomea Fusion beat analyst earnings expectations in its Q1 2025 results, released May 5, 2025. The company reported EPS of -$0.80 versus the -$0.84 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Biomea Fusion EPS Results

Actual EPS
-$0.80
Consensus EPS
-$0.84
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Biomea Fusion Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biomea Fusion Q1 2025 Earnings FAQ

Biomea Fusion (NASDAQ:BMEA) reported earnings of -$0.80 per share for Q1 2025, beating the consensus estimate of -$0.84. The report was announced on Monday, May 5, 2025.

Biomea Fusion Earnings Headlines

My prediction for December 8th
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
Biomea Fusion (BMEA) Projected to Post Quarterly Earnings on Tuesday
See More Biomea Fusion Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biomea Fusion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biomea Fusion and other key companies, straight to your email.

About Biomea Fusion

Biomea Fusion (NASDAQ:BMEA) is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for cancer and metabolic diseases. The company uses its proprietary FUSION System to discover and develop covalent medicines designed to engage disease-relevant protein targets.

Biomea’s lead investigational product is BMF-219, an oral, selective covalent inhibitor of menin. The company has evaluated BMF-219 in clinical studies for certain hematologic malignancies and solid tumors, including acute leukemias and multiple myeloma, and has also investigated its potential in metabolic diseases such as type 2 diabetes. BMF-500 is another investigational program intended to target menin-related biology.

Founded in 2017 and headquartered in Redwood City, California, Biomea Fusion conducts research and clinical development activities aimed at addressing diseases with significant unmet medical needs. The company is led by Thomas Butler, who serves as co-founder, chairman and chief executive officer. Its programs are investigational and have not been approved for commercial use by regulatory authorities.

View Biomea Fusion Profile